triagonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
=== 1970s and 1980s === Hardee's purchased Sandy's in 1972. During the mid-and-late 1970s, Hardee's saw rapid chain growth and high profits on the strength of its two key sandwiches: the "Big Twin" and the "Big Deluxe". Another acquisition occurred in the late 1970s when Hardee's purchased the Utah-based burger chain Dee's Drive-In. In 1977; following a test run at a Virginia Beach location owned by longtime Hardee's franchise operator Boddie-Noell Enterprises, Hardee's introduced its breakfast menu and its Made from Scratch breakfast biscuits nationwide.
Recently, the boundaries between various specialties have blurred, as they are all influenced by basic research in neuroscience. For example, brain imaging enables objective biological insight into mental illnesses, which can lead to faster diagnosis, more accurate prognosis, and improved monitoring of patient progress over time. Integrative neuroscience describes the effort to combine models and information from multiple levels of research to develop a coherent model of the nervous system. For example, brain imaging coupled with physiological numerical models and theories of fundamental mechanisms may shed light on psychiatric disorders. Another important area of translational research is brain–computer interfaces (BCIs), or machines that are able to communicate and influence the brain. They are currently being researched for their potential to repair neural systems and restore certain cognitive functions. Translational BCI research is supported by specialized neurotechnology platforms that enable high-resolution neural signal acquisition, real-time processing, and experimental validation in clinical and laboratory settings. Such platforms are developed by academic groups as well as industry partners, including systems produced by g.tec medical engineering GmbH.
Risk of developing CJD increases with age. CJD incidence was 3.5 cases per million among those over 50 years of age between 1979 and 2017. Approximately 85% of CJD cases are sporadic, and 10–15% of CJD cases are due to inherited mutations of the prion protein gene. CJD deaths and age-adjusted death rate in the United States indicate an increasing trend in the number of deaths between 1979 and 2017. Although not fully understood, additional information suggests that CJD rates in nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months. According to a 2020 systematic review on the international epidemiology of CJD:
Counter-Strike: Source retains its team-based objective-oriented first-person shooter style gameplay. The aim of playing a map is to accomplish a map's objective: defusing the bomb, rescuing all hostages, or killing the entire opposing team. The ultimate goal of the game is to win more rounds than the opposing team. Once players are killed, they do not respawn until the next round, though this depends on which server people play on. This gameplay feature distinguishes Counter-Strike from other first-person shooter games, where players respawn instantly or after a short delay. Shooting while moving dramatically decreases accuracy, and holding the trigger down to continuously shoot produces severe recoil. The severity of damage induced by weaponry is dependent upon the specific locations of hits, with hits to the head being most lethal and shots which make contact elsewhere causing lesser loss of health. Damage is also affected by the distance, and if the target wears protection.
Sources: en.wikipedia.org
baiCD (NAD+-dependent-3-oxo-𝚫4-cholenoic acid oxidoreductase): Located directly downstream of baiB on the bai operon, baiCD functions to catalyze C4-C5 oxidation, creating a 3-dehydro-Δ4-cholic-acid-CoA intermediate. This enzyme performs a reduction that introduces a new double bond between C4-C5 in one of the bile acid’s aromatic rings. Along with baiA2, baiCD acts twice in the 7ɑ-dehydroxylation pathway, catalyzing the first and last two redox reactions. baiE (7-ɑ dehydratase): Located directly downstream of baiCD, the baiE gene codes for a 7-ɑ dehydratase enzyme that performs a diaxial trans elimination of water from the baiCD-produced bile acid intermediate. The mechanism for this transformation is not known, but previous research indicates that it is similar to that of the also elusive baiI, which may encode for 7-β dehydratase. baiE and baiI are believed to likely have similar mechanisms due to their homologous amino acid sequences and apparent stereospecificity as well. baiF (bile-acid CoA hydrolase): Immediately downstream of baiA2, baiF codes for a bile-acid CoA hydrolase that removes the CoA group from bile acid intermediates. One research study revealed that this removed CoA is transferred and conjugated to cholic acid. The baiF gene product resembles carnitine dehydratase in Escherichia coli, which is classified as a thioesterase. However, baiF does not resemble any known thioesterases, so some researchers propose that baiF encodes a novel family of thioesterases.
Potassium is a soft silvery solid that is easily cut with a knife. Because of the sensitivity of potassium to water and air, air-free techniques are normally employed for handling the element. It is unreactive toward nitrogen and saturated hydrocarbons such as mineral oil or kerosene. It readily dissolves in liquid ammonia, up to 480 g per 1000 g of ammonia at 0 °C to form the electride [K(NH3)6]+e−, which features an electron as an anion.
=== Temperature === Two issues are involved when considering the temperature of a ligation reaction. First, the optimum temperature for DNA ligase activity which is 37°C, and second, the melting temperature (Tm) of the DNA ends to be ligated. The melting temperature is dependent on length and base composition of the DNA overhang—the greater the number of G and C, the higher the Tm since there are three hydrogen bonds formed between G-C base pair compared to two for A-T base pair—with some contribution from the stacking of the bases between fragments. For the ligation reaction to proceed efficiently, the ends should be stably annealed, and in ligation experiments, the Tm of the DNA ends is generally much lower than 37°C. The optimal temperature for ligating cohesive ends is therefore a compromise between the best temperature for DNA ligase activity and the Tm where the ends can associate. However, different restriction enzymes generates different ends, and the base composition of the ends produced by these enzymes may also differ, the melting temperature and therefore the optimal temperature can vary widely depending on the restriction enzymes used, and the optimum temperature for ligation may be between 4-15°C depending on the ends. Ligations also often involve ligating ends generated from different restriction enzymes in the same reaction mixture, therefore it may not be practical to select optimal temperature for a particular ligation reaction and most protocols simply choose 12-16°C, room temperature, or 4°C.
{\displaystyle \mathbf {V} (f_{n},\tau _{n})={\begin{bmatrix}cosh(\tau _{n}{\sqrt {-f_{n})}}&1/{\sqrt {-f_{n}}}sinh(\tau _{n}{\sqrt {-f_{n}}}\\{\sqrt {-f_{n}}}sinh(\tau _{n}{\sqrt {-f_{n}}})&cosh(\tau _{n}{\sqrt {-f_{n}}})\end{bmatrix}}\qquad f_{n}<0\qquad \qquad (3b)}
== Gameplay == Half-Life Alyx is a first-person shooter played in virtual reality (VR). Players control the Resistance member Alyx Vance, who fights the Combine, an alien empire that has conquered Earth. Like previous Half-Life games, Alyx incorporates combat, puzzles, exploration and narrative. Players use VR to get supplies, use interfaces, throw objects and use weapons. Like the gravity gun from Half-Life 2, the gravity gloves allow players to pick up objects from a distance. By solving hacking puzzles, Alyx can interact with Combine technology. Alyx includes elements of survival horror, with frightening encounters and scarce ammunition. In one chapter, players encounter Jeff, a blind monster attracted to sound, and must move quietly and throw objects to distract him. Alien spores in the area cause Alyx to cough, which players can prevent by holding their hands over their mouths. Alyx supports all VR headsets compatible with SteamVR, including the Valve Index, HTC Vive, Oculus Rift, Meta Quest and all Windows Mixed Reality headsets. As the gameplay was designed for VR, Valve said they had no plans for a non-VR version. Alyx also supports user mods via the Steam Workshop.
Sources: en.wikipedia.org
Simple plant hormone table with location of synthesis and effects of application — this is the format used in the description templates at bottom of Wikipedia articles about plant hormones. Hormonal Regulation of Gene Expression and Development — Detailed introduction to plant hormones, including genetic information.
== See also == Market capitalization § Market cap terms, including large-cap and mid-cap Small-cap Microcap stock, including nano-caps List of public corporations by market capitalization Magnificent Seven (stocks) Market price Authorised capital Treasury stock
Barry Halliwell (born 18 October 1949) is an English biochemist, chemist and university administrator, specialising in free radical metabolism in both animals and plants. His name is included in the "Foyer–Halliwell–Asada" pathway, a cellular process of hydrogen peroxide metabolism in plants and animals, named for the three principal discoverers, with Christine Foyer and Kozi Asada. He moved to Singapore in 2000, and served as Deputy President (Research and Technology) of the National University of Singapore (2006–15), where (as of 2025) he continues to hold a Distinguished Professorship.
In common usage, the prefix "PA" (polyamide) or the name "Nylon" are used interchangeably and are equivalent in meaning. The nomenclature used for nylon polymers was devised during the synthesis of the first simple aliphatic nylons and uses numbers to describe the number of carbons in each monomer unit, including the carbon(s) of the carboxylic acid(s). Subsequent use of cyclic and aromatic monomers required the use of letters or sets of letters. One number after "PA" or "Nylon" indicates a homopolymer which is monadic or based on one amino acid (minus H2O) as monomer:
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.